- Home
- TLRY vs KALV Comparison
TLRY vs KALV Comparison
Compare TLRY & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLRY | KALV |
|---|---|---|
| Founded | N/A | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 919.2M | 757.7M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TLRY | KALV |
|---|---|---|
| Price | $7.05 | $17.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $103.33 | $30.00 |
| AVG Volume (30 Days) | ★ 2.4M | 554.3K |
| Earning Date | 04-08-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | $7.39 | N/A |
| Revenue Next Year | $4.76 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $0.36 | $9.83 |
| 52 Week High | $15.70 | $19.00 |
Technical Indicators
Market Signals| Indicator | TLRY | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 38.38 | 63.58 |
| Support Level | $1.00 | $14.45 |
| Resistance Level | $8.20 | $17.30 |
| Average True Range (ATR) | 0.35 | 0.72 |
| MACD | -0.04 | 0.12 |
| Stochastic Oscillator | 15.04 | 66.37 |
Price Performance
Historical ComparisonAbout TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.